Response to treatment with daclizumab
| Response on day 43 | |
| Complete response | 16 of 43 (37%) |
| Partial response | 6 of 43 (14%) |
| Failed but alive | 13 of 43 (30%) |
| Death before day 43 | 8 of 43 (19%) |
| Complete response by organ involvement | |
| Skin | 20 of 37 (54%) |
| Liver | 2 of 12 (17%) |
| Gut | 10 of 27 (37%) |
| Complete response by extent | |
| Skin alone | 10 of 16 (63%) |
| Gut alone | 0 of 3 (0%) |
| Multiorgan | 6 of 24 (25%) |
| Complete response by baseline grade | |
| Grade 1-2 | 10 of 23 (43%) |
| Grade 3-4 | 6 of 20 (30%) |
| Complete response by age group | |
| < 18 y | 5 of 12 (42%) |
| ≥ 18 y | 11 of 31 (35%) |
| Complete response by regimen | |
| Regimen 1 | 7 of 24 (29%) |
| Regimen 2 | 9 of 19 (47%) |
| Response on day 43 | |
| Complete response | 16 of 43 (37%) |
| Partial response | 6 of 43 (14%) |
| Failed but alive | 13 of 43 (30%) |
| Death before day 43 | 8 of 43 (19%) |
| Complete response by organ involvement | |
| Skin | 20 of 37 (54%) |
| Liver | 2 of 12 (17%) |
| Gut | 10 of 27 (37%) |
| Complete response by extent | |
| Skin alone | 10 of 16 (63%) |
| Gut alone | 0 of 3 (0%) |
| Multiorgan | 6 of 24 (25%) |
| Complete response by baseline grade | |
| Grade 1-2 | 10 of 23 (43%) |
| Grade 3-4 | 6 of 20 (30%) |
| Complete response by age group | |
| < 18 y | 5 of 12 (42%) |
| ≥ 18 y | 11 of 31 (35%) |
| Complete response by regimen | |
| Regimen 1 | 7 of 24 (29%) |
| Regimen 2 | 9 of 19 (47%) |